SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following reported 700% year-over-year revenue growth, fueled by recent expanded global approvals for its cancer therapies in the EU and Saudi Arabia. The community is buzzing with anticipation of a significant short squeeze and further label expansions, highlighting the immense potential of its diverse immunotherapy platform.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after its CagriSema weight-loss drug trial achieved 23% weight loss but missed its primary endpoint of non-inferiority compared to Eli Lilly's tirzepatide, causing a significant stock drop. The community is debating whether this market reaction is an overblown response to a minor efficacy difference, creating a buying opportunity, or if it signals a tougher competitive landscape against its rival.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is buzzing after securing FDA approval for BYSANTI, its new drug for bipolar I disorder and schizophrenia, a development the community sees as a significant re-rating catalyst due to its New Chemical Entity status and patent protection extending to 2044. This long-term exclusivity is fueling widespread speculation about potential buyout offers from major pharmaceutical companies and the stock's short squeeze potential, even as some investors eye commercial launch timelines and possible dilution.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors digest news of a significant stock sale filing from Trump's trust, fueling community discussions around potential dilution and the company's highly scrutinized financial viability. There is ongoing anticipation of upcoming reports and updates regarding a debated 'fusion deal' amidst concerns about its fundamental value.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending as a recent direct stock offering at $5 sparks debate, with bulls viewing it as a strategic move to fund game-changing MST technology for AI and data centers, while bears voice skepticism over dilution given the company's pre-revenue status and historical performance.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Enthusiasm for MoonLake Immunotherapeutics is surging following stellar Phase 2 S-OLARIS trial results for its lead drug sonelokimab in axial spondyloarthritis, with the community highlighting "best-in-class" efficacy, disease-modifying potential, strong financials, and anticipating further positive updates at its upcoming Investor Day.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx is trending as Gilead Sciences announced its acquisition for $7.8 billion, with the community focusing on the substantial premium and the strategic value of Arcellx's promising CAR T-cell therapy, anito-cel, which has shown strong clinical data for multiple myeloma.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its mainnet launch and institutional validation, including its Coinbase 50 index inclusion, drive bullish conviction in its utility and long-term potential, yet the community remains sharply divided amid persistent price drops leading to strong skepticism about the project's viability.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA granting Priority Review for AXS-05 in Alzheimer's disease agitation, setting an April PDUFA date, alongside robust Q4 earnings and strong commercial growth for its CNS therapies. The community is highly optimistic about AXS-05's market potential and the company's trajectory towards cash flow positivity, further supported by multiple analyst upgrades and pipeline advancements.

20/20 Biolabs, Inc. engages in development and commercialization of proteomics product line. Its products include One Test, PAULA's Test and BioCheck Suspisious Powder Testing Kit. The company was founded by Jonathan Cohen in May 2000 and is headquartered in Gaithersburg, MD.

20/20 Biolabs Inc

AIDX is trending due to extreme post-IPO volatility, experiencing significant declines as community discussion points to a potential "pump and dump" for the newly public direct lister, also facing headwinds from a sector-wide downturn in the liquid biopsy space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Windtree Therapeutics Inc. drew increased retail chatter on Tuesday after disclosing plans to adopt a cryptocurrency policy that would enable it to accept digital currencies as payment and hold them as assets.The stock closed at $0.79, up 5% on Tuesday, but declined 4.9% to $0.75 in after-hours trading.The biotech firm said its board approved the development of the policy, which aims to align with broader digital commerce trends.&nbsp;The move comes as the company pursues a transition toward a revenue-generating model.Windtree added that it is in discussions with several groups that focus on Bitcoin and other cryptocurrencies as potential payment options.&nbsp;The company also said it may hold long-term digital assets as part of a broader treasury strategy.On Stocktwits, retail sentiment was ‘neutral’ amid ‘high’ message volume.One user noted increased buying interest in Windtree, citing low float and crypto-related news.&nbsp;<stembedurl>https://stocktwits.com/makedatbread88/message/616696047</stembedurl>Meanwhile, another user expressed skepticism, saying they had never seen a stock that consistently declines.<stembedurl>https://stocktwits.com/Lord_Andrew_London/message/616705134</stembedurl>The stock has declined 95.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representation of Bitcoin, Ripple, Litecoin and Ethereum cryptocurrencies is seen in this illustration photo taken in Krakow, Poland on June 6, 2021. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Windtree Stock Falls After-Hours As Board Approves Crypto Policy Amid Revenue Diversification Efforts

The company plans to accept and hold cryptocurrencies and is in talks with several groups focused on digital payments.

Equity

U.S. stocks rose on Friday morning as investors digested the latest inflation data, which reinforced expectations of a September interest rate cut. The broader market exhibited a mixed performance in the previous session, with early optimism stemming from strong GDP data fading as tech giants dragged down the Nasdaq and S&amp;P 500.Here’s a look at the top three stocks that captured retail investors’ attention ahead of the opening bell today:Windtree Therapeutics Inc (WINT)<figure class="image"><a href="https://stocktwits.com/symbol/WINT"><img style="aspect-ratio:1316/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/WINT_sentiment_and_message_volume_score_on_Jul_26_58f5cea25d.png" alt="WINT sentiment and message volume score on Jul 26.png" width="1316" height="320"></a><figcaption>WINT sentiment and message volume score premarket on Jul 26</figcaption></figure>Shares of Windtree Therapeutics surged by an impressive 150% in pre-market trading to reach a high $9.40. The biopharma company announced an update on its novel heart failure treatment, istaroxime, igniting a buying frenzy among retail investors.&nbsp;Stocktwits data revealed overwhelmingly bullish sentiment (71/100), with message volume reaching its highest level this year (90/100). While the stock has experienced a significant decline of over 73% year-to-date, today's surge has injected a dose of optimism among investors.Dexcom Inc (DXCM)In stark contrast to Windtree's performance, Dexcom Inc witnessed a dramatic decline of over 36% in pre-market trading, settling in the mid $60s. The medical device company's disappointing second-quarter revenue results and a weak FY24 revenue guidance for its glucose monitoring devices triggered a sell-off. Despite the price drop, several analysts maintained price targets well above current levels, suggesting potential upside in the long term.&nbsp;However, retail investor sentiment on Stocktwits plummeted to its lowest point this year (10/100), reflecting the bearish outlook, while message volumes reached a 2024 peak (96/100). Concerns about management’s inability to adequately communicate business issues and its plan to fix it, as well as market share impacts from the adoption of GLP-1 weight loss drugs is keeping retail away. &nbsp;<figure class="image"><a href="https://stocktwits.com/symbol/DXCM"><img style="aspect-ratio:1324/314;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/DXCM_sentiment_and_message_volume_score_on_Jul_26_17d563e160.png" alt="DXCM sentiment and message volume score on Jul 26.png" width="1324" height="314"></a><figcaption>DXCM sentiment and message volume score premarket on Jul 26</figcaption></figure>Anavex Life Sciences Corporation (AVXL)Shares of Anavex Life Sciences Corporation climbed over 4% in pre-market trading to a high of $7.22, with retail sentiment on Stocktwits at bullish levels (65/100).&nbsp;The neuro-disease-focused biopharma company received a boost from EF Hutton analyst Jason Kolbert, who initiated coverage with a Buy rating and a price target of $46. The analyst highlighted the company's lead therapy, ANAVEX2-73, for Alzheimer's Disease (AD), which is on track for regulatory submission by the end of the year. The potential market for ANAVEX2-73, coupled with its broader therapeutic applications, has fueled investor optimism.<figure class="image"><a href="https://stocktwits.com/symbol/AVXL"><img style="aspect-ratio:1320/312;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AVXL_sentiment_and_message_volume_score_on_Jul_26_d22a8e0bab.png" alt="AVXL sentiment and message volume score on Jul 26.png" width="1320" height="312"></a><figcaption>AVXL sentiment and message volume score premarket on Jul 26</figcaption></figure><a href="https://www.vecteezy.com/photo/29286690-ai-generative-business-man-standing-in-the-stock-market-realistic-image-ultra-hd-high-design-very-detailed">Photo</a> courtesy of syedqaseem on Vecteezy

WINT Soars, DXCM Plunges, AVXL Gains: Retail Investors' Focus Before the Bell

Two stocks are sparking optimism on Stocktwits with watchers passionately discussing potential catalysts, while one is losing a lot of favor following its disappointing earnings and outlook. 

WINT Soars, DXCM Plunges, AVXL Gains: Retail Investors' Focus Premarket

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. It's portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

WINT
Windtree Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest WINT News

WINTWindtree Therapeutics Inc